

FORM PTO 1390 (REV 5-93)		US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371		ATTORNEY DOCKET NUMBER 2006_0834A	
		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/581,255	
International Application No. PCT/JP2004/018038	International Filing Date December 3, 2004	Priority Date Claimed December 5, 2003	
Title of Invention INHIBITOR OF PROTEIN MODIFICATION PRODUCTS FORMATION			
Applicant(s) For DO/EO/US Toshio MIYATA and Kiyoshi KUROKAWA			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. §371. 2. <input checked="" type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. §371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1). 4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> A <u>replacement</u> translation of the International Application into English (35 U.S.C. §371(c)(2)). <b>ATTACHMENT A1</b> 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)). a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19. 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)). <b>Items 11. to 14. below concern other document(s) or information included:</b> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> Other items or information:			

<b>U.S. APPLICATION NO.</b> (if known, see 37 CFR 1.5) 10/581,255		<b>INTERNATIONAL APPLICATION NO.</b> PCT/JP2004/018038		<b>ATTORNEY'S DOCKET NO.</b> 2006_0834A	
15. <input type="checkbox"/> The following fees are submitted				CALCULATIONS	PTO USE ONLY
Basic National Stage Fee ..... \$300.00 National Stage Search Fee (International Search Report provided - 37 CFR 1.492(b)(2)) ..... \$400.00 National Stage Examination Fee ..... \$200.00 Specification/drawings in excess of 100 pages (units of 50 x \$250.00) = ..... \$					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$0	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	- 20 =		X \$50.00	\$	
Independent Claims	- 3 =		X \$200.00	\$	
Multiple dependent claim(s) (if applicable)			+ \$360.00	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$0	
<input type="checkbox"/> Small Entity Status is hereby asserted. Above fees are reduced by 1/2.				\$	
<b>SUBTOTAL =</b>				\$0	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$
<b>TOTAL NATIONAL FEE =</b>				\$0	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$0	
				Amount to be refunded	\$
				Amount to be charged	\$
a. <input type="checkbox"/> A check in the amount of \$ to cover the above fees is enclosed. A duplicate copy of this form is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 23-0975 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0975.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
19. CORRESPONDENCE ADDRESS   <div style="text-align: center;"> <b>CUSTOMER NO.</b>  <b>000513</b> </div>			<div style="border: 1px solid black; padding: 5px;"> <p style="text-align: center;">             THE COMMISSIONER IS              TO CHARGE ANY DEFERRED              FEES FOR THIS PAPER              ACCOUNT NO. 23-0975           </p> <p style="text-align: center;">             AUTHORIZED              AGENCY IN THE              DEPOSIT           </p> </div> <div style="margin-top: 10px;">             By: <u>Matthew M. Jacob</u>              Matthew M. Jacob,              Registration No. 25,154               WENDEROTH, LIND &amp; PONACK, L.L.P.              2033 "K" Street, N.W., Suite 800              Washington, D.C. 20006-1021              Phone: (202) 721-8200              Fax: (202) 721-8250               July 20, 2006           </div>		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Toshio MIYATA et al. : **Mail Stop: PCT**  
Serial No. 10/581,255 : Attorney Docket No. 2006\_0834A  
Filed May 31, 2006 :

INHIBITOR OF PROTEIN MODIFICATION  
PRODUCTS FORMATION  
[Corresponding to PCT/JP2004/018038  
Filed December 3, 2004]

**COVER LETTER FOR REPLACEMENT ENGLISH TRANSLATION  
OF THE SPECIFICATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith is a replacement copy of the English translation (Attachment A), previously submitted when this National Stage application was filed.

The presently filed translation differs from the previously filed translation in that Table 1 was originally omitted.

In this regard, see the last line on page 68 of the previously filed English translation.

The name of the chemical compounds listed in Table 1 are shown on pages 36 to 42 of the previously filed English translation.

Kindly employ the enclosed replacement English translation of the specification of this application.

Respectfully submitted,

Toshio MIYATA et al.

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

By Matthew M. Jacob  
Matthew M. Jacob  
Registration No. 25,154  
Attorney for Applicants

MJ/kes  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
July 20, 2006